Promising Top|Line Results Testing Trofinetide to Treat Rett Syndrome

Positive Top-line Results for Phase 3 Trofinetide Trial

Positive top-line results for trofinetide began years ago when IRSF recognized treatment potential in Rett syndrome and made major financial ...

Promising Top-Line Results Testing Trofinetide to Treat Rett Syndrome

Kathie Bishop, PhD, Chief Scientific Officer at Acadia Pharmaceuticals, discusses the positive top-line results from the pivotal phase 3 ...

Is trofinetide a future treatment for Rett syndrome? A comprehensive ...

Rett syndrome (RTT) is a rare, life-threatening, genetic neurodevelopmental disorder. Treatment in RTT encounters many challenges. Trofinetide, ...

Acadia Pharmaceuticals Announces Positive Top-line Results from ...

Trofinetide has been granted Fast Track Status and Orphan Drug Designation for Rett syndrome. Trofinetide has also been granted Rare Pediatric ...

Trofinetide receives FDA approval as first drug for Rett syndrome

Trofinetide, an oral medication sold under the brand name Daybue, has just received FDA approval for the treatment of RTT, an uncommon gene- ...

Clinical Trial News & Updates

The following companies are actively conducting clinical trials in individuals with Rett syndrome. This stage may take 6-7 years to complete the 3 phases of ...

Double-blind, randomized, placebo-controlled study of trofinetide in ...

Trofinetide at 200 mg/kg bid showed statistically significant and clinically relevant improvements relative to placebo on the Rett Syndrome Behaviour ...

Trofinetide—a new chapter in rett syndrome's treatment - Frontiers

Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2 years or above.

Trofinetide Treatment Demonstrates a Benefit Over Placebo for the ...

Trofinetide was approved by the US Food and Drug Administration for the treatment of Rett syndrome (RTT) in March 2023. Benefiting the ability to ...

Design and outcome measures of LAVENDER, a phase 3 study of ...

Rett syndrome (RTT) is a neurodevelopmental disorder without approved treatment. · Trofinetide is an investigational drug for the treatment of RTT. · LAVENDER ...

Acadia Pharmaceuticals Announces Positive Top-line Results

These are encouraging results for patients and families affected by Rett syndrome. · results support a potential treatment for Rett syndrome and ...

Potential Rett syndrome drug shows promising results in phase 3 trial

A potential first-of-its-kind drug to treat the symptoms of Rett syndrome received positive top-line results from a phase 3 trial.

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett ...

“The data reported in this study show that females treated with trofinetide experienced lessened neurobehavioral impairments including social ...

Trofinetide: A Promising New Treatment for Rett Syndrome

The promising results of Trofinetide in treating Rett syndrome have led researchers to investigate its potential for treating autism. As both Rett syndrome ...

FDA Approves Acadia's Trofinetide for Rett Syndrome - NeurologyLive

The FDA has approved trofinetide (Daybue; Acadia Pharmaceuticals) for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older.

Trofinetide for Rett Syndrome: Highlights on the Development and ...

Recently, Trofinetide was approved by the USFDA on 10 March 2023 as the first RTT treatment. This article underlines the pharmaceutical advancement, patent ...

Rett Syndrome: The Emerging Landscape of Treatment Strategies

Trofinetide is the first US Food and Drug Administration approved product for the specific treatment of RTT. 1 Introduction. Specific treatment ...

Trofinetide Clinical Trial Results Published

IGF analogs are considered the most promising approach for treating Rett Syndrome, a fatal genetic disorder that affects only girls.

'Encouraging' Results Seen in Patients in LAVENDER Phase 3 Trial

Trofinetide significantly reduced neurobehavioral symptoms and improved communication in females with Rett syndrome, the LAVENDER trial ...

Trofinetide Treatment Demonstrates a Benefit Over Placebo for the ...

Background: Trofinetide was approved by the US Food and Drug Administration for the treatment of Rett syndrome (RTT) in March 2023.